EU/3/16/1812

About

On 12 January 2017, orphan designation (EU/3/16/1812) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for antroquinonol for the treatment of pancreatic cancer.

The sponsorship was transferred to FGK Representative Service GmbH, Germany, in January 2019.

Key facts

Active substance
Antroquinonol
Medicine name
-
Disease / condition
Treatment of pancreatic cancer
Date of first decision
12/01/2017
Outcome
Positive
EU designation number
EU/3/16/1812

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

FGK Representative Service GmbH
Heimeranstrasse 35
80339 Munich
Germany
Tel.+49 8989 311928
E-mail: clinical.studies@fgk-rs.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating